Product news

Share this article:
The FDA has approved Sucampo Pharmaceuticals' supplemental NDA for Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women 18 years of age or older. As a result of the approval, Sucampo Pharmaceuticals will receive a development milestone payment of $50 million from Takeda in accordance a prior licensing agreement. Sucampo Pharmaceuticals and Takeda will jointly market Amitiza in the US and Canada. 
 
The FDA approved Watson Pharmaceuticals' Mixject, a new delivery system for Trelstar (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.